|Awarded On||February 21, 2019|
|Title||Interleukin-15– and -21–Armored Glypican-3–Specific CAR T Cells for Patients With Hepatocellular Carcinoma|
|Award Mechanism||Individual Investigator Research Awards for Clinical Translation|
|Institution/Organization||Baylor College of Medicine|
|Principal Investigator/Program Director||Andras Heczey|
|Cancer Sites||Gallbladder, Liver and Intrahepatic Bile Duct|
*Pending contract negotiation
Hepatocellular carcinoma (HCC) is the commonest type of liver cancer. There will be over 20000 new patients diagnosed this year in the United States, and Texas has the highest rate of HCC in the US. Most patients cannot be cured and die from their disease. We propose a new type of treatment using the patients’ own immune system. We will collect special cells from the blood called T cells. We put a new gene in these T cells that allows them to recognize and kill the HCC cells. This gene is called GPC3-CAR. We have also added two extra genes called interleukin-15 and interleukin-21 (IL-15/21), which should make the GPC3-CAR T cells even more effective in killing HCC and allow them to last lon...